Biocon FY26 Results: Revenue Grows to Rs 17,270 Cr, Net Debt Down

Revenue from operations for Biocon Limited in FY26 reached Rs 17,270 crore, an increase from Rs 16,470 crore in FY25. The company's net debt saw a significant reduction, standing at Rs 10,332 crore in FY26 compared to Rs 12,830 crore in FY25.

Reader Takeaway: Revenue growth and deleveraging are positives, but margin contraction is a key concern.

What just happened

Biocon announced its financial results for the fiscal year 2026. Total revenue grew by approximately 4.9% to Rs 17,270 crore. The company's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) decreased to Rs 3,798 crore from Rs 4,374 crore in the previous fiscal year, indicating a contraction in profitability margins. A major positive development is the reduction in net debt to Rs 10,332 crore.

Why this matters

The revenue growth indicates sustained demand for Biocon's products. The substantial reduction in net debt is crucial for financial health and may lead to lower interest costs. However, the decline in EBITDA and overall margins, especially within the Generics segment, signals increased competition or pricing pressures that could impact future profitability.

The backstory

Biocon operates across three key segments: Biosimilars, Generics, and Contract Research, Development, and Manufacturing Services (CRDMO). The company has been actively consolidating its Biocon Biologics business and undertaking strategic debt refinancing. In the previous fiscal year (FY25), revenue stood at Rs 16,470 crore with EBITDA at Rs 4,374 crore and net debt at Rs 12,830 crore.

What changes now

Biocon has completed the consolidation of its Biologics business and refinanced acquisition debt, aiming for operational efficiencies and improved financial flexibility. The company is poised to launch five new biosimilars and key GLP-1 products in FY27, which are expected to drive future growth. The successful deleveraging aims to reduce annual interest expenses by approximately Rs 300 crore.

Risks to watch

The primary risk highlighted is the continued pressure on EBITDA margins, particularly the sharp decline in the Generics segment's margin to 5% from 12%. Further deterioration in pricing power or increased operating costs could negatively affect earnings. Monitoring the success of new product launches and their contribution to margin improvement is critical.

Peer comparison

While specific peer data for FY26 is not provided in the filing, the Generics segment's margin pressure is a common theme across the Indian pharmaceutical industry due to intense competition and regulatory hurdles. Companies focusing on specialty products and complex generics often exhibit better margin profiles.

Context metrics (time-bound)

• Revenue Growth (FY26 vs FY25): ~4.9%
• EBITDA (FY26): Rs 3,798 crore (vs. Rs 4,374 crore in FY25)
• Net Debt (FY26): Rs 10,332 crore (vs. Rs 12,830 crore in FY25)
• Generics EBITDA Margin (FY26): 5% (vs. 12% in FY25)
• Overall EBITDA Margin (FY26): 22% (vs. 27% in FY25)

What to track next

Investors will be closely watching the impact of new biosimilar and GLP-1 product launches on revenue and profitability in FY27. The company's ability to manage costs, reverse margin contraction in the Generics segment, and further optimize its debt structure will be key performance indicators.